Compare Harley-Davidson Inc (HOG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs BIO-TECHNE Corp — how do they compare? Harley-Davidson Inc trades at $26.67 (market cap $2.72B), while BIO-TECHNE Corp trades at $72.05 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 4.1× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| HOG | TECH | |
|---|---|---|
Market Cap | $2.72B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $72.29 |
52-Week Low | $17.19 | $43.31 |
Enterprise Value | $3.13B | $11.32B |
Dividend Yield | 2.82% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.01, up 1.21% daily, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q2 2026 EPS of $0.75, beating estimates, and raised full-year guidance. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin at 4.78%. Valuation ratios appear attractive with a P/E of 14.45 and P/B of 0.87. Recent news highlights North American sales strength and a strategic shift to U.S. production.
The outlook is cautiously optimistic; earnings beat and raised guidance support upside, but declining revenue and margin pressures pose risks. Analyst consensus is mixed with a $26 price target. Key risks include competitive threats and raw material costs. The stock's valuation discount offers potential if turnaround efforts gain traction.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
